Anti-cancer vaccines — a one-hit wonder?

Yale Journal of Biology and Medicine

Volumn 87, Issue 4, 2014, Pages 481-489

  Liu, Justin K H ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti cancer vaccines; Cancer immunotherapy; Personalized therapy; Preventive vaccines; Therapeutic vaccines

Indexed keywords

CANCER VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; MELANOMA VACCINE; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TECEMOTIDE; WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; GRANULOMA; HUMAN; IMMUNOGENICITY; LIVER CELL CARCINOMA; LYMPHOCYTE ACTIVATION; MELANOMA; NON SMALL CELL LUNG CANCER; PROSTATE CANCER; SIDE EFFECT ASSESSMENT; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VITILIGO; DRUG DEVELOPMENT; ECONOMICS; IMMUNOLOGY; NEOPLASMS;

BACTERIA (MICROORGANISMS);

CANCER VACCINES; DRUG DISCOVERY; HUMANS; NEOPLASMS;

EID: 84928553458     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Gilboa E. The Promise of Cancer Vaccines. Nat Rev Cancer. 2004;4(5):401-11.
2. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for Tumour Prevention. Nat Rev Cancer. 2006;6(3):204-16.
3. Schlom J. Therapeutic Cancer Vaccines: Current Status and Moving Forward. J Natl Cancer Inst. 2012;104(8):599-613.
4. Nour NM. Cervical Cancer: A Preventable Death. Rev Obstet Gynecol. 2009;2(4):240-4.
5. Finn OJ. Cancer Vaccines: Between the Idea and Reality. Nat Rev Immunol. 2003;3(8):630-41.
6. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic Cancer Vaccines: Past, Present and Future. Adv Cancer Res. 2013;119:421-75.
7. Coulie PG, Van den Eynde BJ, van den Bruggen P, Boon T. Tumour Antigens Recognised by T-Lymphocytes: At the Core of Cancer Immunotherapy. Nat Rev Cancer. 2014;14(2):135-46.
8. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating Tumour Antigens Into Cancer Vaccines. Clin Vaccine Immunol. 2011;18(1):23-34.
9. Amos SM, Duong CPM, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity Associated with Immunother-apy of Cancer. Blood. 2011;118(3):499-509.
10. Cheever MA, Higano CS. PROVENGE (Sip-uleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine. Clin Cancer Res. 2011;17(11):3520-6.
11. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, et al. Sipuleucel-T. Nat Rev Drug Discov. 2010;9(7):513-4.
12. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T Im-munotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010;363(5):411-22.
13. Schiller JT, Lowy DR. Vaccines to Prevent Infections by Oncoviruses. Ann Rev Micro-biol. 2010;64:23-41.
14. Garland SM, Smith JS. Human Papillo-mavirus Vaccines: Current Status and Future Prospects. Drugs. 2010;70(9):1079-98.
15. Stanley M. Prophylactic HPV Vaccines. J Clin Pathol. 2007;60(9):961-5.
16. Cutts FT, Franceschi S, Goldie S, Castell-sague X, de Sanjose S, Garnett G, et al. Human Papillomavirus and HPV Vaccines: A Review. Bull World Health Organ. 2007;85(9):719-26.
17. Kitchener HC, Denton K, Soldan K, Crosbie EJ. Developing Role of HPV in Cervical Cancer Protection. BMJ. 2013;347:f4781.
18. Pomfret TC, Gagnon Jr JM, Gilchrist AT. Quadrivalent Human Papillomavirus (HPV) Vaccine: A Review of Safety, Efficacy and Pharmacoeconomics. J Clin Pharm Ther. 2011;36(1):1-9.
19. HPV Vaccines. Centers for Disease Control and Prevention [Internet]. [cited 2014 Sep 3]. Available from: http://www.cdc.gov/hpv/vac-cine.html.
20. Gerlich WH. Medical Virology of Hepatitis B: How It Began and Where We Are Now. Virol J. 2013;10:239.
21. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B Virus Infection: Epidemiology and Vaccination. Epidemiol Rev. 2006;28(1):112-25.
22. Aspinall EJ, Hawkins G, Fraser A, Hutchin-son SJ, Goldberg D. Hepatitis B Prevention, Diagnosis, Treatment and Care: A Review. Occup Med (Lond). 2011;61(8):531-40.
23. Gerber JS, Offit PA. Vaccines and Autism: A Tale of Shifting Hypotheses. Clin Infect Dis. 2009;48(4):456-61.
24. Elliman D, Bedford H. MMR: Where Are We Now? Arch Dis Child. 2007;92(12):1055-7.
25. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to Human Papillomavirus Vaccination Among US Adolescents: A Systematic Review of the Literature. JAMA Pediatr. 2014;168(1):76-82.
26. Hopkins TG, Wood N. Female Human Papil-lomavirus (HPV) Vaccination: Global Uptake and the Impact of Attitudes. Vaccine. 2013;31(13):1673-9.
27. Kudrin A. Business Models and Opportunities for Cancer Vaccine Developers. Hum Vaccin Immunother. 2012;8(10):1431-8.
28. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 Peptide Vaccine and Interleukin-2 in Patients With Advanced Melanoma. N Engl J Med. 2011;364(22):2119-27.
29. Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, et al. Three Phase II Cy-tokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma. J Clin Oncol. 2008;26(14):2292-8.
30. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC-1 and Spontaneous Mouse Tumour Models for Understanding the Immunobiol-ogy of Human Adenocarcinomas. Immunol Res. 2011;50(2-3):261-8.
31. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the Treatment of Non-Small Cell Lung Cancer: Investigational Approaches and Clinical Experience. Lung Cancer. 2011;73(1):11-7.
32. Houot R, Levy R. Vaccines for Lymphomas: Idiotype Vaccines and Beyond. Blood Rev. 2009;23(3):137-42.
33. Bendandi M. Idiotype Vaccines for Lym-phoma: Proof-of-Principles and Clinical Trial Failures. Nat Rev Cancer. 2009;9(9):675-81.
34. Ladjemi MZ. Anti-Idiotypic Antibodies as Cancer Vaccines: Achievements and Future Improvements. Front Oncol. 2012;2:158.
35. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines. Clin Dev Immunol. 2010;2010:814397.
36. Grisham RN, Berek J, Pfisterer J, Sabbatini P. Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer. Immunotherapy. 2011;3(2):153-62.
37. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and Prognostic Factors Associated With Overall Survival Employing a Poxviral-Based PSA Vaccine in Metastatic Castrate-Resistant Prostate Cancer. Cancer Immunol Immunother. 2010;59(5):663-74.
38. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall Survival Analysis of a Phase II Randomised Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2010;28(7):1099-105.
39. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A Randomised Phase II Trial of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer. Clin Cancer Res. 2006;12(4):1260-9.
40. Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, et al. Analysis of Overall Survival in Patients With Non-metastatic Castration-Resistant Prostate Cancer Treated With Vaccine, Nilumatide and Combination Therapy. Clin Cancer Res. 2008;14(14):4526-31.
41. Meacham CE, Morrison SJ. Tumour Heterogeneity and Cancer Cell Plasticity. Nature. 2013;501(7467):328-37.
42. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-74.
43. Curiel T. Tregs and Rethinking Cancer Im-munotherapy. J Clin Invest. 2007;117(5):1167-74.
44. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and Clinical Responses in Patients With Metastatic Melanoma to CD34+ Progenitor-Derived Dendritic Cell Vaccine. Cancer Res. 2001;61(17):6451-8.
45. Luiten RM, Kueter EWM, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, et al. Im-munogenicity Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumour Cells in Metastatic Melanoma Patients. J Clin Oncol. 2005;23(35):8978-91.
46. Reed SG, Orr MT, Fox CB. Key Roles of Adjuvants in Modern Vaccines. Nat Med. 2013;19(12):1597-1608.
47. Dubensky Jr TW, Reed SG. Adjuvants for Cancer Vaccines. Semin Immunol. 2010;22(3):155-61.
48. Petrovsky N, Aguilar JC. Vaccine Adjuvants: Current State and Future Trends. Immunol Cell Biol. 2004;82(5):488-96.
49. Casella CR, Mitchell TC. Putting Endotoxin to Work For Us: Monophosphoryl Lipid A as a Safe and Effective Vaccine Adjuvant. Cell Mol Life Sci. 2008;65(20):3231-40.
50. Didierlaurent AM, Morel S, Lockman L, Gi-annini SL, Bisteau M, Carlsen H, et al. AS04, An Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity. J Immunol. 2009;183(10):6186-97.
51. Newman PA, Logie CH, Doukas N, Asakura K. HPV Vaccine Acceptability Among Men: A Systematic Review and Meta-Analysis. Sex Transm Infect. 2013;89(7):568-74.
52. Kim JJ, Goldie SJ. Cost Effectiveness Analysis of Including Boys in a Human Papillo-mavirus Vaccination Programme in the United States. BMJ. 2009;339:b3884.
53. Brisson M, van de Velde N, Franco EL, Dro-let M, Boily MC. Incremental Impact of Adding Boys to Current Human Papillo-mavirus Vaccination Programs: Role of Herd Immunity. J Infect Dis. 2011;204(3):372-6.
54. Kim JJ. Targeted Human Papillomavirus Vaccination of Men Who Have Sex With Men in the USA: A Cost-Effectiveness Modelling Analysis. Lancet Infect Dis. 2010;10(12):845-52.
55. English P. Should Universal Hepatitis B Immunisation be Introduced in the UK? Arch Dis Child. 2006;91(4):286-9.